View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSirona Biochem 将来の成長Future 基準チェック /06現在、 Sirona Biochemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長-11.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.New Risk • Jan 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.2m (US$9.13m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.2m market cap, or US$9.13m).New Risk • Oct 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.0m market cap, or US$9.38m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding).New Risk • Sep 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Negative equity (-CA$3.1m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (CA$16.8m market cap, or US$12.4m).New Risk • Jun 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$3.1m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.36m).New Risk • Jun 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$2.8m). Revenue is less than US$1m (CA$36k revenue, or US$27k). Minor Risk Market cap is less than US$100m (CA$15.4m market cap, or US$11.2m).New Risk • May 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$12.8m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.8m). Revenue is less than US$1m (CA$36k revenue, or US$27k). Market cap is less than US$10m (CA$12.8m market cap, or US$9.38m). Minor Risk Share price has been volatile over the past 3 months (17% average weekly change).お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.New Risk • Apr 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.1m free cash flow). Negative equity (-CA$2.8m). Revenue is less than US$1m (CA$36k revenue, or US$27k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$16.6m market cap, or US$12.2m).Reported Earnings • Mar 01Full year 2023 earnings released: CA$0.01 loss per share (vs CA$0.015 loss in FY 2022)Full year 2023 results: CA$0.01 loss per share (improved from CA$0.015 loss in FY 2022). Net loss: CA$2.54m (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.New Risk • Dec 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.9m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$1.3m). Revenue is less than US$1m (CA$84k revenue, or US$63k). Minor Risk Market cap is less than US$100m (CA$20.3m market cap, or US$15.0m).お知らせ • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.Reported Earnings • Mar 02Full year 2022 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in FY 2021)Full year 2022 results: CA$0.015 loss per share (further deteriorated from CA$0.01 loss in FY 2021). Revenue: CA$671.9k (up 151% from FY 2021). Net loss: CA$3.56m (loss widened 54% from FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Dec 10Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326Sirona Biochem Corp. announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022. The trial, which will take place in Paris, is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients. The trial design was done with the assistance of a leading organization in commercial aesthetics. It will consist of 20 participants, aged 40-65 with specific signs of aging. Participants will begin in weeks 1 through 3 as a rolling start and continue for a 12-week period using the product twice daily. Ten parameters will be measured using advanced technology. These include skin radiance, skin laxity, antioxidant analysis, anti-inflammation, wrinkles, skin plumping and product tolerance. The clinical trial is fully financed, owned and controlled by Sirona.お知らせ • Nov 17Sirona Biochem Corp. Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326Sirona Biochem Corp. announced positive results of the clinical safety study for their novel anti-aging compound TFC-1326 1% in formulation, now proven to be a non-irritant and non-sensitizer. TFC-1326, Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles. The safety study, which was conducted in Europe under the control of a dermatologist, is a Human Repeat Insult Patch Test with Challenge (HRIPT). The main goal of the HRIPT is to confirm that the application of the investigational product (under maximizing conditions of exposure in a panel of healthy human adult subjects) does not induce delayed contact sensitization and secondarily, to assess the skin compatibility of the formulation. TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies. The study population included 100 healthy individuals aged 18-70. Applications were repeated 9-times to the same site (induction site) over a period of 3 consecutive weeks. After a minimal 2-week rest period, with no product application, a single application of the investigational product was placed under a patch to both the induction site and a new site, to reveal a possible induced allergy (challenge phase). In parallel, distilled water is placed under a patch at the same defined times as the investigational product to act as a control site. Sirona’s anti-aging compound at 1% in the formulation did not cause irritation, sensitization or allergy in any subject. The results of the HRIPT study are necessary to move to the efficacy clinical trial which remains scheduled to start in early December.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jason Tian was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 02Sirona Biochem Corp., Annual General Meeting, Dec 30, 2022Sirona Biochem Corp., Annual General Meeting, Dec 30, 2022.Reported Earnings • Sep 30Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (in line with 3Q 2021). Revenue: CA$653.9k (up CA$624.8k from 3Q 2021). Net loss: CA$381.1k (loss narrowed 23% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 01First half 2022 earnings released: CA$0.011 loss per share (vs CA$0.007 loss in 1H 2021)First half 2022 results: CA$0.011 loss per share (down from CA$0.007 loss in 1H 2021). Net loss: CA$2.81m (loss widened 86% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Jun 21Sirona Biochem Corp. Announces Appointment of Wolfgang Bieber to Advisory Board and Act as A Consultant to the Board of DirectorsSirona Biochem Corp. announced that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act as a consultant to the Board of Directors with immediate effect.Dr. Wolfgang Bieber brings to Sirona Biochem 30 years of experience from his career at BAYER AG, He headed Technical Operations of biological products in the US and the agrochemical production worldwide as Senior VP (direct expense US$300 million, capital expense US$200 million, direct head count 1,250). Among the biological products, Kogenate®, reached annual sales of USD 1 billion. Dr. Bieber was also strongly involved in M&A activities of BAYER AG; Dr. Bieber will provide active and significant support in the following areas: Connecting to chemical manufactures in Europe. Assisting with the conclusion of a partnership of Sirona Biochem’s animal health project. Organizational development of TFChem to accelerate pipeline development.Structuring Sirona Biochem for sustainable growth. Attracting Institutional Investors for Sirona Biochem.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jason Tian was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 04Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.01 loss per share (up from CA$0.018 loss in FY 2020). Revenue: CA$268.0k (up 154% from FY 2020). Net loss: CA$2.31m (loss narrowed 44% from FY 2020). Revenue missed analyst estimates by 5.1%. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Dec 21Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing FacilitySirona Biochem Corp. announced the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University'sInstitute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19). The results will be completed in approximately 6 weeks.お知らせ • Sep 23Sirona Biochem Corp. Announces Discovery of Anti-Cellulite Activity in CompoundsSirona Biochem Corp. reported that In Vitro studies completed on compounds developed by scientists at TFChem have shown a strong potential for anti-cellulite activity. The data showed evidence for both the ability to reduce existing cellulite and to prevent the formation of new cellulite. The mechanism of action is technically complex involving a pro-lipolytic effect, a decrease of the adipocyte size and an anti-inflammatory effect. Company's Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy and her team have created a development plan and will begin the safety testing required for a clinical trial. Specific details of the compounds will be communicated immediately following the filing of patents. Cellulite is the development of orange-peel like skin, particularly in the thigh and buttock area due to fat under the skin and often develops further with aging. There are currently no truly effective therapies to treat cellulite. The global market size was valued at USD 1.4 Billion in 2020 and is expected to have a compounded annual growth rate of 11.0%.Reported Earnings • Jul 02Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: CA$190.9k (up CA$190.4k from 2Q 2020). Net loss: CA$836.6k (loss widened 37% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.お知らせ • Mar 11Sirona Biochem Announces Launch of First Commercial Product Containing TFC-1067Sirona Biochem Corp. announced the launch of the first commercial product containing the Company's proprietary ingredient, TFC-1067. TFC-1067 will debut as the active ingredient in New Rodan + Fields REVERSE Targeted Dark Spot Corrector. It will precisely target stubborn discoloration for a brighter, even-looking skin tone. In Rodan + Fields clinical trials*, REVERSE Targeted Dark Spot Corrector had the following results: After 4 Weeks: 77% had less visible dark spots, After 8 Weeks: 72% didn't feel like their dark spots were the first thing people noticed, Rodan + Fields additional claims: Diminishes the appearance of stubborn dark spots without leaving a halo, Stubborn dark spots look smaller, less defined, less intense, Skin tone looks more uniform and even, Stubborn dark spots are less visible, less noticeable, Skin looks clearer, more translucent.Is New 90 Day High Low • Mar 05New 90-day high: CA$0.46The company is up 107% from its price of CA$0.22 on 03 December 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.Is New 90 Day High Low • Feb 05New 90-day high: CA$0.43The company is up 61% from its price of CA$0.27 on 06 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.Is New 90 Day High Low • Jan 19New 90-day high: CA$0.34The company is up 26% from its price of CA$0.27 on 20 October 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.お知らせ • Oct 27Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic DermatologySirona Biochem Corp. announced that the clinical study using .2% TFC-1067 and conducted by Dr. Zoe Draelos of Dermatology Consulting Services, North Carolina, has been peer reviewed and accepted for publication in the Journal of Cosmetic Dermatology. The 12-week double blinded study involving 48 participants, completed in 2019, showed that TFC-1067 successfully achieved the endpoint of lightening dyschromic areas (dark spots) on the skin. With the application of TFC-1067, areas of hyperpigmentation were significantly lightened while preserving overall skin tone. TFC-1067 demonstrated the ability to lighten dark spots to blend into surrounding skin while preserving overall complexion. In this study, TFC-1067 achieved this goal while Hydroquinone did not, which is a tremendous consumer benefit and commercial advantage. Further studies are planned, with one currently underway. Exploring the potential of TFC-1067 on different skin types, formulations and concentrations will further unlock the consumer and commercial unique benefits.お知らせ • Oct 13Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067Sirona Biochem Corp. announced that it has signed an agreement with a top 10 global pharmaceutical company to jointly test Sirona's novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4%) and advanced formulation. The clinical trial, launched October 5th, will run for a period of 12 weeks and include a minimum of 125 participants. It will be managed by Dermscan (a division of Eurofins), a global leader in cosmetic clinical trials. The study's endpoint is to determine the compound's ability to reduce hyperpigmentation or "dark spots" of the skin. Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. The study is expected to complete in early 2021 with results in February 2021. The study protocol was established through a collaboration of the scientific teams of TFChem, Sirona's wholly owned subsidiary and the company's skincare scientific team. Following the study, the Company will have first access to the clinical study results to assess potential use by its subsidiary dermatology company.Reported Earnings • Oct 02Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$5.03m, with losses widening by 29% from the prior year.Is New 90 Day High Low • Oct 02New 90-day high: CA$0.29The company is up 9.0% from its price of CA$0.27 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sirona Biochem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:SBM - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数7/31/20240-3-2-2N/A4/30/20240-2-2-2N/A1/31/20240-3-2-2N/A10/31/20230-3-2-2N/A7/31/20230-2-2-2N/A4/30/20231-2-2-2N/A1/31/20231-2-2-2N/A10/31/20221-4-2-2N/A7/31/20221-3-2-2N/A4/30/20220-4-2-2N/A1/31/20220-4-2-2N/A10/31/20210-2-2-2N/A7/31/20210-2-3-2N/A4/30/20210-3-3-3N/A1/31/20210-3-2-2N/A10/31/20200-4-2-2N/A7/31/20200-5-3-3N/A4/30/20200-5-3-3N/A1/31/20200-6-4-4N/A10/31/20190-5-4-4N/A7/31/20190-4-3-3N/A4/30/20191-2-2-2N/A1/31/20191-2-1-1N/A10/31/20181-1-1-1N/A7/31/20181-3-1-1N/A4/30/20181-4N/A-2N/A1/31/20181-4N/A-2N/A10/31/20170-4N/A-2N/A7/31/20170-3N/A-3N/A4/30/20170-3N/A-2N/A1/31/20170-3N/A-2N/A10/31/20160-3N/A-2N/A7/31/20160-3N/A-2N/A4/30/20160-3N/A-3N/A1/31/20160-4N/A-3N/A10/31/20150-4N/A-3N/A7/31/20150-3N/A-2N/A4/30/20150-3N/A-2N/A1/31/20150-3N/A-2N/A10/31/20140-4N/A-2N/A7/31/20140-4N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SBMの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SBMの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SBMの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SBMの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SBMの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SBMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/06/02 09:35終値2025/03/05 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sirona Biochem Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Ellis AcklinFirst Berlin Equity Research GmbHJens HasselmeierFirst Berlin Equity Research GmbH
お知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.
お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.
New Risk • Jan 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.2m (US$9.13m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.2m market cap, or US$9.13m).
New Risk • Oct 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$3.5m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.0m market cap, or US$9.38m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding).
New Risk • Sep 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Negative equity (-CA$3.1m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (CA$16.8m market cap, or US$12.4m).
New Risk • Jun 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$3.1m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.36m).
New Risk • Jun 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$2.8m). Revenue is less than US$1m (CA$36k revenue, or US$27k). Minor Risk Market cap is less than US$100m (CA$15.4m market cap, or US$11.2m).
New Risk • May 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$12.8m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.8m). Revenue is less than US$1m (CA$36k revenue, or US$27k). Market cap is less than US$10m (CA$12.8m market cap, or US$9.38m). Minor Risk Share price has been volatile over the past 3 months (17% average weekly change).
お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.
New Risk • Apr 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.1m free cash flow). Negative equity (-CA$2.8m). Revenue is less than US$1m (CA$36k revenue, or US$27k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$16.6m market cap, or US$12.2m).
Reported Earnings • Mar 01Full year 2023 earnings released: CA$0.01 loss per share (vs CA$0.015 loss in FY 2022)Full year 2023 results: CA$0.01 loss per share (improved from CA$0.015 loss in FY 2022). Net loss: CA$2.54m (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.
お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.
お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.
New Risk • Dec 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.9m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$1.3m). Revenue is less than US$1m (CA$84k revenue, or US$63k). Minor Risk Market cap is less than US$100m (CA$20.3m market cap, or US$15.0m).
お知らせ • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.
Reported Earnings • Mar 02Full year 2022 earnings released: CA$0.015 loss per share (vs CA$0.01 loss in FY 2021)Full year 2022 results: CA$0.015 loss per share (further deteriorated from CA$0.01 loss in FY 2021). Revenue: CA$671.9k (up 151% from FY 2021). Net loss: CA$3.56m (loss widened 54% from FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Dec 10Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326Sirona Biochem Corp. announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022. The trial, which will take place in Paris, is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients. The trial design was done with the assistance of a leading organization in commercial aesthetics. It will consist of 20 participants, aged 40-65 with specific signs of aging. Participants will begin in weeks 1 through 3 as a rolling start and continue for a 12-week period using the product twice daily. Ten parameters will be measured using advanced technology. These include skin radiance, skin laxity, antioxidant analysis, anti-inflammation, wrinkles, skin plumping and product tolerance. The clinical trial is fully financed, owned and controlled by Sirona.
お知らせ • Nov 17Sirona Biochem Corp. Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326Sirona Biochem Corp. announced positive results of the clinical safety study for their novel anti-aging compound TFC-1326 1% in formulation, now proven to be a non-irritant and non-sensitizer. TFC-1326, Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles. The safety study, which was conducted in Europe under the control of a dermatologist, is a Human Repeat Insult Patch Test with Challenge (HRIPT). The main goal of the HRIPT is to confirm that the application of the investigational product (under maximizing conditions of exposure in a panel of healthy human adult subjects) does not induce delayed contact sensitization and secondarily, to assess the skin compatibility of the formulation. TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies. The study population included 100 healthy individuals aged 18-70. Applications were repeated 9-times to the same site (induction site) over a period of 3 consecutive weeks. After a minimal 2-week rest period, with no product application, a single application of the investigational product was placed under a patch to both the induction site and a new site, to reveal a possible induced allergy (challenge phase). In parallel, distilled water is placed under a patch at the same defined times as the investigational product to act as a control site. Sirona’s anti-aging compound at 1% in the formulation did not cause irritation, sensitization or allergy in any subject. The results of the HRIPT study are necessary to move to the efficacy clinical trial which remains scheduled to start in early December.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jason Tian was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 02Sirona Biochem Corp., Annual General Meeting, Dec 30, 2022Sirona Biochem Corp., Annual General Meeting, Dec 30, 2022.
Reported Earnings • Sep 30Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (in line with 3Q 2021). Revenue: CA$653.9k (up CA$624.8k from 3Q 2021). Net loss: CA$381.1k (loss narrowed 23% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 01First half 2022 earnings released: CA$0.011 loss per share (vs CA$0.007 loss in 1H 2021)First half 2022 results: CA$0.011 loss per share (down from CA$0.007 loss in 1H 2021). Net loss: CA$2.81m (loss widened 86% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Jun 21Sirona Biochem Corp. Announces Appointment of Wolfgang Bieber to Advisory Board and Act as A Consultant to the Board of DirectorsSirona Biochem Corp. announced that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act as a consultant to the Board of Directors with immediate effect.Dr. Wolfgang Bieber brings to Sirona Biochem 30 years of experience from his career at BAYER AG, He headed Technical Operations of biological products in the US and the agrochemical production worldwide as Senior VP (direct expense US$300 million, capital expense US$200 million, direct head count 1,250). Among the biological products, Kogenate®, reached annual sales of USD 1 billion. Dr. Bieber was also strongly involved in M&A activities of BAYER AG; Dr. Bieber will provide active and significant support in the following areas: Connecting to chemical manufactures in Europe. Assisting with the conclusion of a partnership of Sirona Biochem’s animal health project. Organizational development of TFChem to accelerate pipeline development.Structuring Sirona Biochem for sustainable growth. Attracting Institutional Investors for Sirona Biochem.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jason Tian was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 04Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.01 loss per share (up from CA$0.018 loss in FY 2020). Revenue: CA$268.0k (up 154% from FY 2020). Net loss: CA$2.31m (loss narrowed 44% from FY 2020). Revenue missed analyst estimates by 5.1%. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Dec 21Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing FacilitySirona Biochem Corp. announced the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University'sInstitute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19). The results will be completed in approximately 6 weeks.
お知らせ • Sep 23Sirona Biochem Corp. Announces Discovery of Anti-Cellulite Activity in CompoundsSirona Biochem Corp. reported that In Vitro studies completed on compounds developed by scientists at TFChem have shown a strong potential for anti-cellulite activity. The data showed evidence for both the ability to reduce existing cellulite and to prevent the formation of new cellulite. The mechanism of action is technically complex involving a pro-lipolytic effect, a decrease of the adipocyte size and an anti-inflammatory effect. Company's Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy and her team have created a development plan and will begin the safety testing required for a clinical trial. Specific details of the compounds will be communicated immediately following the filing of patents. Cellulite is the development of orange-peel like skin, particularly in the thigh and buttock area due to fat under the skin and often develops further with aging. There are currently no truly effective therapies to treat cellulite. The global market size was valued at USD 1.4 Billion in 2020 and is expected to have a compounded annual growth rate of 11.0%.
Reported Earnings • Jul 02Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: CA$190.9k (up CA$190.4k from 2Q 2020). Net loss: CA$836.6k (loss widened 37% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
お知らせ • Mar 11Sirona Biochem Announces Launch of First Commercial Product Containing TFC-1067Sirona Biochem Corp. announced the launch of the first commercial product containing the Company's proprietary ingredient, TFC-1067. TFC-1067 will debut as the active ingredient in New Rodan + Fields REVERSE Targeted Dark Spot Corrector. It will precisely target stubborn discoloration for a brighter, even-looking skin tone. In Rodan + Fields clinical trials*, REVERSE Targeted Dark Spot Corrector had the following results: After 4 Weeks: 77% had less visible dark spots, After 8 Weeks: 72% didn't feel like their dark spots were the first thing people noticed, Rodan + Fields additional claims: Diminishes the appearance of stubborn dark spots without leaving a halo, Stubborn dark spots look smaller, less defined, less intense, Skin tone looks more uniform and even, Stubborn dark spots are less visible, less noticeable, Skin looks clearer, more translucent.
Is New 90 Day High Low • Mar 05New 90-day high: CA$0.46The company is up 107% from its price of CA$0.22 on 03 December 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.
Is New 90 Day High Low • Feb 05New 90-day high: CA$0.43The company is up 61% from its price of CA$0.27 on 06 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.
Is New 90 Day High Low • Jan 19New 90-day high: CA$0.34The company is up 26% from its price of CA$0.27 on 20 October 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
お知らせ • Oct 27Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic DermatologySirona Biochem Corp. announced that the clinical study using .2% TFC-1067 and conducted by Dr. Zoe Draelos of Dermatology Consulting Services, North Carolina, has been peer reviewed and accepted for publication in the Journal of Cosmetic Dermatology. The 12-week double blinded study involving 48 participants, completed in 2019, showed that TFC-1067 successfully achieved the endpoint of lightening dyschromic areas (dark spots) on the skin. With the application of TFC-1067, areas of hyperpigmentation were significantly lightened while preserving overall skin tone. TFC-1067 demonstrated the ability to lighten dark spots to blend into surrounding skin while preserving overall complexion. In this study, TFC-1067 achieved this goal while Hydroquinone did not, which is a tremendous consumer benefit and commercial advantage. Further studies are planned, with one currently underway. Exploring the potential of TFC-1067 on different skin types, formulations and concentrations will further unlock the consumer and commercial unique benefits.
お知らせ • Oct 13Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067Sirona Biochem Corp. announced that it has signed an agreement with a top 10 global pharmaceutical company to jointly test Sirona's novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4%) and advanced formulation. The clinical trial, launched October 5th, will run for a period of 12 weeks and include a minimum of 125 participants. It will be managed by Dermscan (a division of Eurofins), a global leader in cosmetic clinical trials. The study's endpoint is to determine the compound's ability to reduce hyperpigmentation or "dark spots" of the skin. Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. The study is expected to complete in early 2021 with results in February 2021. The study protocol was established through a collaboration of the scientific teams of TFChem, Sirona's wholly owned subsidiary and the company's skincare scientific team. Following the study, the Company will have first access to the clinical study results to assess potential use by its subsidiary dermatology company.
Reported Earnings • Oct 02Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$5.03m, with losses widening by 29% from the prior year.
Is New 90 Day High Low • Oct 02New 90-day high: CA$0.29The company is up 9.0% from its price of CA$0.27 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.